Scholar Rock Holding Corporation Common Stock
SRRK
$51.27
+4.23%
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics for the treatment of serious diseases, with a primary emphasis on rare, severe, and debilitating neuromuscular conditions such as Spinal Muscular Atrophy (SMA). The company is a niche player in the biotechnology sector, distinguished by its proprietary platform targeting the activation of latent growth factors, particularly myostatin, to promote muscle growth. The current investor narrative is intensely focused on the clinical and regulatory progress of its lead candidate, apitegromab, as the company transitions from a pure R&D entity to a potential commercial-stage biotech, with recent attention driven by key data readouts and the anticipation of a Biologics License Application (BLA) submission.…
SRRK
Scholar Rock Holding Corporation Common Stock
$51.27
Investment Opinion: Should I buy SRRK Today?
Rating: Hold. The core thesis is that while SRRK possesses a promising pipeline and strong analyst backing, its extreme valuation and binary risk profile at current prices offer an unfavorable risk/reward balance for new capital. Supporting evidence includes the unanimous 'Buy' analyst sentiment, but the absence of quantified price targets limits upside clarity. The company's robust liquidity (current ratio 6.95) and manageable debt (D/E 0.44) are positive, yet they are offset by intense cash burn (-$300.64M FCF TTM) and deep unprofitability (EPS -$0.74). The stock trades at a staggering PB of 20.58, a premium that demands flawless execution. While future revenue potential is large (avg. est. $837.5M), the path to achieving it is fraught with risk. The two biggest risks that could invalidate a Hold thesis are 1) a clinical/regulatory failure for apitegromab, and 2) a severe equity dilution event to fund operations. This Hold would upgrade to a Buy if the stock corrected meaningfully (e.g., towards the $30-$35 range) offering a better entry point, or upon confirmation of a successful BLA submission and acceptance without dilution. It would downgrade to a Sell on any adverse clinical news or if quarterly cash burn accelerated beyond -$100 million. Relative to its history and the inherent risks of its stage, the stock is overvalued.
Sign up to view all
SRRK 12-Month Price Forecast
The outlook is bifurcated and highly event-dependent. The neutral stance reflects the offsetting forces of bullish analyst conviction and a dangerously rich valuation for a pre-revenue company. The base case (50% probability) envisions range-bound trading as the story unfolds, with the stock already pricing in significant success. The stance would upgrade to bullish on a successful BLA acceptance coupled with a non-dilutive financing solution, or a pullback to the mid-$30s improving the risk/reward. It would turn bearish on any clinical setback or a massively dilutive capital raise.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Scholar Rock Holding Corporation Common Stock's 12-month outlook, with a consensus price target around $66.65 and implied upside of +30.0% versus the current price.
Average Target
$66.65
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$41 - $67
Analyst target range
Insufficient analyst coverage data is available in the provided dataset to determine a consensus price target, buy/hold/sell distribution, or target range. The data includes institutional ratings actions but not specific price targets. The presence of recent ratings from multiple firms like JP Morgan, Barclays, and Citigroup, all maintaining 'Buy' or 'Overweight' equivalents as recently as March 2026, indicates ongoing and bullish analyst sentiment. However, without quantified targets, the implied upside or downside cannot be calculated. The implications of limited explicit target data are significant; while the company is covered by several reputable firms, the absence of published targets may reflect the high uncertainty and binary nature of the investment tied to clinical outcomes. A wide target spread would be expected among analysts, with high targets pricing in successful commercialization and market penetration for apitegromab, while low targets would account for clinical setbacks or commercial challenges. The consistent 'Buy' ratings from all reporting firms in Q1 2026 suggest a strong, bullish consensus view on the company's prospects, but investors must rely on clinical catalysts rather than traditional valuation anchors.
Bulls vs Bears: SRRK Investment Factors
The bull case, supported by unanimous analyst 'Buy' ratings and a strong balance sheet, currently holds stronger evidence, as it is backed by concrete financial capacity and professional sentiment. However, the bear case presents severe fundamental risks rooted in the absence of revenue and steep losses. The single most critical tension in the SRRK investment debate is the clash between its extreme valuation (PB of 20.58) and its pre-revenue, cash-burning clinical-stage reality. The resolution of this tension depends entirely on the flawless clinical and regulatory execution for apitegromab; success justifies the premium, while any stumble triggers a potentially catastrophic derating.
Bullish
- Strong Analyst Consensus: All reporting firms (JP Morgan, Barclays, Citigroup) maintain 'Buy' or 'Overweight' ratings as of March 2026, indicating a high-conviction bullish sentiment on the company's clinical and commercial prospects. This consensus is a significant vote of confidence for a pre-revenue biotech.
- Robust Balance Sheet & Liquidity: The company has a strong current ratio of 6.95 and a manageable debt-to-equity ratio of 0.44, providing ample financial runway to fund operations through key clinical and regulatory milestones. Recent equity issuance of $73.29 million in Q4 2025 further bolsters the cash position.
- Significant Future Revenue Potential: Analyst revenue estimates average $837.5 million, with a high-end projection of $1.13 billion, representing massive potential growth upon successful commercialization of apitegromab. The market cap of ~$5.05 billion reflects anticipation of this future revenue stream.
- Favorable Long-Term Price Trend: The stock has gained +30.31% over the past year, outperforming the SPY's +24.99% return, and trades at 84% of its 52-week range ($27.07 to $52.185). This sustained uptrend signals strong investor optimism regarding the company's transition toward commercialization.
Bearish
- No Revenue & Deeply Unprofitable: The company is pre-revenue with quarterly revenue of $0 and reported a net loss of -$90.97 million in Q4 2025. With a trailing EPS of -$0.74 and negative ROE of -154%, the business model is entirely dependent on future clinical success and external financing.
- Extreme Valuation on Book Value: The price-to-book (PB) ratio of 20.58 is exceptionally high, indicating the market is pricing in near-perfect execution and significant future value from intangible pipeline assets. This leaves the stock vulnerable to severe multiple compression if clinical progress stumbles.
- Intense Cash Burn & Negative FCF: The company reported negative free cash flow of -$75.53 million for Q4 2025 and -$300.64 million TTM. This high cash burn rate necessitates future dilutive equity offerings or debt raises to fund operations, posing a persistent overhang on the stock.
- Recent Relative Underperformance: Over the past 3 months, SRRK gained +6.03%, significantly underperforming the SPY's +15.14%. This recent divergence from market strength suggests waning momentum and potential consolidation after its strong 1-year run, trading near yearly highs.
SRRK Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a significant 1-year price change of +30.31%, outperforming the SPY's +24.99% gain. As of the latest data, the price of $47.33 positions it at approximately 84% of its 52-week range ($27.07 to $52.185), indicating it is trading closer to its yearly highs, which reflects strong investor optimism but also suggests potential vulnerability to profit-taking. The short-term momentum, however, has diverged negatively from the longer-term trend; the stock declined -0.48% over the past month and gained only +6.03% over the past three months, underperforming the SPY's respective gains of +0.74% and +15.14%. This 1-month underperformance signals a potential consolidation or pullback within the broader uptrend, possibly due to market digestion of recent gains or sector-specific headwinds. Key technical support is anchored at the 52-week low of $27.07, while immediate resistance sits near the 52-week high of $52.185. A decisive breakout above $52.185 would signal a resumption of the primary bullish trend and could target new highs, whereas a breakdown below the recent consolidation range around $40-$43 would suggest a deeper correction. The stock exhibits a beta of 0.695, indicating it has been approximately 30% less volatile than the broader market over the measured period, which is atypical for a clinical-stage biotech and may reflect its progression toward commercialization, reducing binary event risk. The price action over the last six months shows a gain of +7.81%, which lags the SPY's +9.72% return, further highlighting a recent period of relative underperformance. The stock's Relative Strength Index (RSI) data is not explicitly provided, but the price's position near yearly highs combined with negative short-term momentum suggests the RSI may be cooling from potentially overbought levels. The substantial short interest, with a short ratio of 12.86, indicates a significant bearish bet against the stock, which could fuel a sharp rally on positive news (a short squeeze) but also underscores the high-risk, high-reward perception among traders.
Beta
0.69
0.69x market volatility
Max Drawdown
-34.9%
Largest decline past year
52-Week Range
$27-$52
Price range past year
Annual Return
+54.1%
Cumulative gain past year
| Period | SRRK Return | S&P 500 |
|---|---|---|
| 1m | +6.5% | -1.6% |
| 3m | +12.9% | +11.7% |
| 6m | +11.8% | +6.3% |
| 1y | +54.1% | +22.2% |
| ytd | +19.8% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SRRK Fundamental Analysis
Scholar Rock is a pre-revenue company, as evidenced by quarterly revenue of $0 for the most recent quarter ending December 31, 2025, and across all provided periods. The investment thesis is entirely predicated on future revenue potential from its pipeline, with analyst estimates projecting average annual revenue of approximately $837.5 million, ranging from a low of $506.4 million to a high of $1.13 billion, indicating significant expected growth upon commercialization. The multi-quarter trend shows no revenue generation, which is standard for a company at this development stage, and the focus is squarely on the progression of clinical trials toward regulatory approval. The company is deeply unprofitable, reporting a net income of -$90.97 million and an EPS of -$0.74 for Q4 2025. Gross profit was negative -$425,000, resulting in a gross margin of 0%, which reflects costs associated with manufacturing and development activities without product sales. While losses are substantial, the quarterly net income has shown some volatility, improving from -$110.03 million in Q2 2025 to -$90.97 million in Q4 2025, but the trend is not consistently toward narrowing losses, as seen in the sequential increase from -$74.72 million in Q1 2025. The operating loss of -$91.90 million for Q4 2025 underscores the heavy investment in research and development, which totaled $46.45 million for the quarter. The balance sheet remains robust with a strong current ratio of 6.95, indicating ample liquidity to cover short-term obligations. The debt-to-equity ratio is a manageable 0.44, suggesting a conservative capital structure that is not overly reliant on debt financing. However, cash flow is a critical concern; the company reported negative free cash flow of -$75.53 million for Q4 2025 and a trailing twelve-month free cash flow of -$300.64 million. The negative return on equity of -154% and return on assets of -54.3% highlight the intense capital consumption inherent in its business model. The company is dependent on external financing to fund its operations, as evidenced by significant common stock issuances, such as the $73.29 million raised in Q4 2025.
Quarterly Revenue
$0.0B
2025-12
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
$-300637000.0B
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SRRK Overvalued?
Given that Net Income is deeply negative and EBITDA is also negative at -$83.82 million, the primary valuation metric selected is the Price-to-Sales (PS) ratio, as the company has no current sales, and the EV-to-Sales ratio is also not calculable from standard revenue. The trailing Price-to-Sales ratio is 0, and a forward PS cannot be calculated without a current market price, but the market is valuing the company based on its future sales potential, with a market cap of approximately $5.05 billion against analyst revenue estimates averaging $837.5 million, implying a forward PS multiple that the market will assess upon commercialization. Peer comparison for standard valuation multiples like PE or PS is not meaningful as the company has no revenue or earnings. The valuation is entirely driven by the net present value of its pipeline assets. The stock's price-to-book (PB) ratio of 20.58 is extremely high, reflecting that the company's value is almost entirely in intangible assets (IP, pipeline) not captured on the balance sheet, rather than tangible book equity. This premium to book value is typical for successful biotech firms but signifies high expectations. Historically, the stock's own valuation ratios show extreme ranges due to its clinical-stage nature. The trailing PE ratio has fluctuated from as high as -3.01 in September 2024 to -13.89 in December 2025, with the current PE of -13.37 near the more negative (less optimistic) end of its recent band. The PB ratio has expanded significantly from 1.80 in December 2022 to 20.58 currently, indicating the market has progressively priced in greater success probability for its lead program, placing the stock near historical valuation highs, which embeds very optimistic expectations for clinical and regulatory success.
PE
-13.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -17x~-1x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and immediate. Scholar Rock is a pre-revenue company burning cash at a rate of -$300.64 million TTM, with net losses of -$90.97 million last quarter. The business model is entirely dependent on the success of its lead candidate, apitegromab, creating a binary outcome. While the balance sheet is currently strong (current ratio 6.95), the intense cash burn necessitates future capital raises, which will likely be dilutive to existing shareholders given the lack of earnings. The negative ROE of -154% and ROA of -54.3% highlight the extreme capital intensity and inefficiency of its current R&D-focused operations. Market & Competitive Risks are elevated due to valuation and sector dynamics. Trading at a PB ratio of 20.58, near its 52-week high, the stock embeds near-perfect clinical and commercial execution. This premium valuation is highly susceptible to compression from sector-wide de-risking, rising interest rates impacting biotech discount rates, or competitive developments in the SMA and neuromuscular treatment landscape. The stock's beta of 0.695 suggests it has been less volatile than the market, but this is atypical for a clinical-stage biotech and may not hold during a clinical catalyst or sector sell-off. Worst-Case Scenario involves a material clinical setback for apitegromab, such as failed trial data or a Complete Response Letter from the FDA. This would trigger a collapse in the pipeline's net present value, leading to massive multiple compression. Analyst revenue estimates would be slashed, and the stock would likely re-test its 52-week low of $27.07 as investor confidence evaporates. From the current price of ~$47.33, this scenario implies a realistic downside of approximately -43%. Combined with the potential for accelerated cash burn and dilutive financing in a distressed scenario, total losses could exceed 50%.
FAQ
The key risks are, in order of severity: 1) Clinical/Regulatory Risk: Failure or delay of lead candidate apitegromab would collapse the investment thesis, with downside to the 52-week low of $27.07 (-43%). 2) Financial Risk: The company burns over $75 million per quarter, necessitating future dilutive equity offerings. 3) Valuation Risk: The extreme PB multiple of 20.58 is vulnerable to compression on any negative news. 4) Competitive Risk: Evolving treatment landscape for Spinal Muscular Atrophy could challenge apitegromab's commercial potential.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $45 and $55 as it progresses its BLA submission, with a target near the current price. The Bull Case (25% probability) targets $60 to $75 on flawless clinical/regulatory execution and partnership news. The Bear Case (25% probability) targets $27 to $35 on clinical setbacks or severe dilution. The most likely outcome is the Base Case, assuming the company meets expected timelines without major surprises, but the stock's rich valuation limits near-term upside.
SRRK is significantly overvalued based on standard financial metrics, as it has no revenue or earnings. The extreme Price-to-Book ratio of 20.58 indicates the market is valuing intangible pipeline potential at a massive premium to tangible assets. This valuation implies the market expects successful commercialization of apitegromab achieving analyst revenue estimates averaging $837.5 million. Compared to its own history, the PB ratio has expanded from 1.80 in late 2022 to over 20 today, placing it at a peak valuation that leaves no room for error.
SRRK is not a good buy for most investors at its current price near $47.33. While analyst sentiment is unanimously bullish and the pipeline is promising, the stock is overvalued with a Price-to-Book ratio of 20.58, embedding near-perfect success. The risk/reward is unfavorable due to the binary clinical nature, intense cash burn (-$300.64M TTM FCF), and high probability of future shareholder dilution. It may be a speculative buy only for highly risk-tolerant investors on a significant pullback, such as towards the $30-$35 range, which would offer a better margin of safety.
SRRK is unsuitable for short-term trading due to its binary event-driven nature and lower beta (0.695), which may limit trading volatility absent news. It is a long-term, speculative investment with a minimum suggested holding period of 2-3 years to see through key clinical, regulatory, and initial commercial milestones. The stock pays no dividend and offers no earnings visibility, making it purely a capital appreciation story dependent on pipeline success. Only investors with a long horizon and high risk tolerance should consider a position.